Tesamorelin Canada: GH-Axis Product Guide, COA & Purity Review
Quick answer: Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH) that stimulates the body’s own growth hormone release. Unlike many research peptides, it’s an approved prescription drug in some jurisdictions (FDA-approved as Egrifta for a specific condition). As with any peptide, quality is judged by a batch-specific COA showing HPLC purity and mass spec identity.
Tesamorelin is a growth-hormone-axis peptide that, like a handful of others, has actually been through formal drug approval. This article explains what it is, how the GHRH-analog mechanism works, where it stands with regulators, and how to read a COA for it — keeping to mechanism and documentation rather than usage.
What Tesamorelin is
Tesamorelin is a synthetic analog of GHRH (growth-hormone-releasing hormone), the hypothalamic hormone that signals the pituitary to release growth hormone. It’s a stabilized version designed to resist the rapid breakdown that natural GHRH undergoes.
Unlike most compounds sold as “research peptides,” Tesamorelin completed clinical trials and regulatory review for a defined medical indication, which makes it a more thoroughly characterized molecule than most.
How the GHRH-analog mechanism works
Growth hormone release is governed by the hypothalamus through two opposing signals: GHRH stimulates it, somatostatin suppresses it. GH is then released in pulses.
Tesamorelin works by mimicking GHRH — binding to GHRH receptors on the pituitary and stimulating GH release along the body’s natural pathway. Because it acts upstream (prompting the body’s own GH release) rather than supplying growth hormone directly, its mechanism is described as working “with” the natural pulsatile pattern. The structural stabilization is what gives it a longer active life than native GHRH.
Regulatory status
Like bremelanotide, Tesamorelin sits apart from most research peptides on this point:
It’s an approved drug in some jurisdictions. In the US, the FDA approved Tesamorelin (brand name Egrifta) for a specific condition. That reflects a level of clinical evaluation most research peptides never undergo.
In Canada, verify its current Health Canada status directly, as approval varies by jurisdiction and changes over time. The key point: even where approved, Tesamorelin is a prescription medicine for a defined use under medical supervision — not a general consumer product. Material sold as a “research” peptide sits outside that approved, supervised framework.
That distinction is the one that matters: an approved prescription drug is meant to be used under medical supervision for a diagnosed condition, which is different from sourcing the compound independently.
Reading a COA for Tesamorelin
For any peptide, the COA separates verifiable quality from a claim. A legitimate one is batch-specific — tied to the exact lot — not a generic PDF reused across products.
Header details
- Product name (Tesamorelin) and sequence
- Batch or lot number matching the physical product label
- Test date, recent and plausible
- Named testing lab, ideally independent
HPLC purity
- A purity percentage, ideally 98% or higher
- The actual chromatogram — one dominant target peak, minimal impurities — not just a stated number
Mass spec identity
- An observed molecular weight matching the expected weight for the sequence
- Confirms it’s the right molecule; purity alone doesn’t
Verification
- Match the batch number to your product
- Confirm the lab exists and is named
- Watch for reused COAs across batches
You can review available COA records here to see what batch-specific documentation should look like, and the Tesamorelin listing should show stated purity, form, and batch details.
Purity & storage checklist
| Element | What to confirm |
|---|---|
| Batch number | Matches the physical product |
| Test date | Recent and plausible |
| HPLC purity | 98%+, with a visible chromatogram |
| Mass spec | Observed weight matches expected |
| Lab | Named, independent, verifiable |
| Form | Lyophilized stores better than solution |
| Batch-specific | Not reused across products |
Frequently asked questions
What is Tesamorelin?
A synthetic GHRH analog that stimulates the body’s own growth hormone release. Unusually for a research peptide, it’s an approved prescription drug in some jurisdictions.
How does it work?
It mimics GHRH, binding to pituitary GHRH receptors to prompt natural, pulsatile GH release — acting upstream rather than supplying GH directly.
Is Tesamorelin approved in Canada?
Verify current status with Health Canada directly. It’s FDA-approved in the US (as Egrifta) for a specific condition; even where approved, it’s a supervised prescription medicine, not a general consumer product.
What purity should a Tesamorelin COA show?
For research applications, 98%+ supported by an HPLC chromatogram, plus mass spec confirmation of identity.
How do I verify a COA is legitimate?
Match the batch number to your product, confirm the date is plausible, check the named lab exists, and ensure the COA isn’t reused across batches.
This article is for informational and educational purposes. It is not medical advice and does not recommend the use of any compound. Where a compound is an approved prescription medicine, it is intended for use under medical supervision.
